## Trabectedin-d3

**MedChemExpress** 

Cat. No.: Molecular Formula: Molecular Weight: Target: Pathway: Storage:	HY-50936S C <sub>39</sub> H <sub>40</sub> D <sub>3</sub> N <sub>3</sub> O <sub>11</sub> S 764.86 Reactive Oxygen Species; Apoptosis; Isotope-Labeled Compounds Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; Apoptosis; Others -20°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)	
---	--	--

BIOLOGICAL ACTIVITY		
BIOLOGICALMONT		
Description	Trabectedin D3 (Ecteinascidin 743 D3) is deuterium labeled Trabectedin. Trabectedin is a tetrahydroisoquinoline alkaloid with potent antitumor activity. Trabectedin binds to the minor groove of DNA, blocks transcription of stress-induced proteins, induces DNA backbone cleavage and cancer cells apoptosis, and increases the generation of ROS in MCF-7 and MDA-MB-453 cells. Trabectedin has tje potential for soft tissue sarcoma and ovarian cancer treatment <sup>[1][2][3]</sup> .	

## REFERENCES

[1]. Takahashi N, et al. Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and NSC 125973 in human breast cancer cell linesin vitro and in vivo. Cancer Res. 2002 Dec 1;62(23):6909-15.

[2]. Atmaca H, et al. A diverse induction of apoptosis by trabectedin in MCF-7 (HER2-/ER+) and MDA-MB-453 (HER2+/ER-) breast cancer cells. Toxicol Lett. 2013 Jun 20;221(2):128-136.

[3]. Germano G, et al. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res. 2010 Mar 15;70(6):2235-44.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Product Data Sheet